Literature DB >> 20513333

An analysis of the mixing efficiency of neutral protamine Hagedorn cartridges.

Scott V Monte1, Patrick Comerford, Natalie Dearing.   

Abstract

In this issue of Journal of Diabetes Science and Technology, Kaiser and colleagues conducted an investigation to identify variations in the delivered dose of several different isophane insulin (neutral protamine Hagedorn, NPH) brands that use glass and metal bodies ("bullets") to facilitate mixing. Using a strategy where multiple pens from each of five different NPH insulin products (Insuman Basal, sanofi-aventis, three metal bullets; Humulin N, Lilly, one glass bullet; Berlinsulin H Basal, Berlin-Chemie, one glass bullet; Insulin B. Braun Basal, two glass bullets; and Protaphane Penfill, NovoNordisk, one glass bullet) were compared at multiple sampling points and over a range of mixing procedures (3, 6, 10, and 20 times), the authors identified deviations in the delivered dose of insulin at initial use and with repeated dosing. At the initial dose, adhering with manufacturer recommendations to conduct the mixing procedure 10-20 times was found to demonstrate minimal deviation and there was no pronounced difference among the products. Decreasing the number of mixing procedures from 10-20 to 3-6 times, a more profound deviation was noted, with the Insuman Basal product demonstrating less variability in comparison to all other products evaluated. A repeated dose study (1, 2, 6, and 10) with only six mixing procedures revealed that the insulin concentration of each dose increased for all products except Insuman Basal. Clinically, numerous factors may contribute to variability observed with subcutaneous administration of isophane insulin. While data presented by Kaiser and colleagues demonstrated that the issue of proper mixing is not trivial, the modest differences observed between and within products both at the initial dose and with repeated dosing may indicate that the clinical relevance of these findings is most applicable to those requiring large doses or, alternatively, those who have otherwise unexplained hypoglycemic episodes. (c) 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20513333      PMCID: PMC2901044          DOI: 10.1177/193229681000400321

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  9 in total

1.  Variation in absorption of NPH insulin due to intramuscular injection.

Authors:  A Vaag; A Handberg; M Lauritzen; J E Henriksen; K D Pedersen; H Beck-Nielsen
Journal:  Diabetes Care       Date:  1990-01       Impact factor: 19.112

2.  Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients.

Authors:  V A Koivisto; P Felig
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

Review 3.  Reproducibility and variability in the action of injected insulin.

Authors:  H Gin; H Hanaire-Broutin
Journal:  Diabetes Metab       Date:  2005-02       Impact factor: 6.041

4.  Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

Authors:  P M Jehle; C Micheler; D R Jehle; D Breitig; B O Boehm
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

Review 5.  Variability of insulin absorption and insulin action.

Authors:  Lutz Heinemann
Journal:  Diabetes Technol Ther       Date:  2002       Impact factor: 6.118

Review 6.  Subcutaneous insulin: pharmacokinetic variability and glycemic variability.

Authors:  B Guerci; J P Sauvanet
Journal:  Diabetes Metab       Date:  2005-09       Impact factor: 6.041

7.  Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges.

Authors:  Pia Kaiser; Sebastian Maxeiner; Alexander Weise; Florain Nolden; Anja Borck; Thomas Forst; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

Review 8.  Insulin pharmacokinetics.

Authors:  C Binder; T Lauritzen; O Faber; S Pramming
Journal:  Diabetes Care       Date:  1984 Mar-Apr       Impact factor: 19.112

9.  Absorption of isophane (NPH) insulin and its clinical implications.

Authors:  T Lauritzen; S Pramming; E A Gale; T Deckert; C Binder
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-17
  9 in total
  1 in total

Review 1.  Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.

Authors:  Juergen Sandow; Wolfgang Landgraf; Reinhard Becker; Gerhard Seipke
Journal:  Eur Endocrinol       Date:  2015-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.